CAR-T cells Infusion chimeric antigen receptor T cells
CT0596-CG6022_02
Phase 1 small_molecule active
Quick answer
CAR-T cells Infusion chimeric antigen receptor T cells for Relapsed/Refractory Plasma Cell Leukemia is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Relapsed/Refractory Plasma Cell Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active